Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Legros

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Oncogene|September 28, 2005
A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysisA Jacquel, M Herrant, V Defamie, et al.
FEBS Letters|October 20, 1999
Creation of a functional S-nitrosylation site in vitro by single point mutationC Castro, F A Ruiz, I Pérez-Mato, et al.
Leukemia|February 27, 2009
Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapyD Rea, G Etienne, S Corm, et al.
Plos One|April 9, 2013
A new device to mimic intermittent hypoxia in miceKamil J Chodzyński, Stephanie Conotte, Luc Vanhamme, et al.
Leukemia|March 31, 2012
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemiaD Rea, G Etienne, F Nicolini, et al.
Leukemia|June 4, 2011
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaC Roche-Lestienne, A Marceau, E Labis, et al.
Leukemia|May 1, 2015
The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cellsL Mourgues, V Imbert, M Nebout, et al.
Leukemia|January 27, 2006
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemiaD Rea, L Legros, E Raffoux, et al.
British Journal of Haematology|May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II studyL Mannone, C Gardin, M C Quarre, et al.
Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Oncogene|September 28, 2005
A survey of the signaling pathways involved in megakaryocytic differentiation of the human K562 leukemia cell line by molecular and c-DNA array analysisA Jacquel, M Herrant, V Defamie, et al.
FEBS Letters|October 20, 1999
Creation of a functional S-nitrosylation site in vitro by single point mutationC Castro, F A Ruiz, I Pérez-Mato, et al.
Leukemia|February 27, 2009
Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapyD Rea, G Etienne, S Corm, et al.
Plos One|April 9, 2013
A new device to mimic intermittent hypoxia in miceKamil J Chodzyński, Stephanie Conotte, Luc Vanhamme, et al.
Leukemia|March 31, 2012
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemiaD Rea, G Etienne, F Nicolini, et al.
Leukemia|June 4, 2011
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaC Roche-Lestienne, A Marceau, E Labis, et al.
Leukemia|May 1, 2015
The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cellsL Mourgues, V Imbert, M Nebout, et al.
Leukemia|January 27, 2006
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemiaD Rea, L Legros, E Raffoux, et al.
British Journal of Haematology|May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II studyL Mannone, C Gardin, M C Quarre, et al.
Leukemia Research|December 20, 2011
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?R Itzykson, S Thépot, O Beyne-Rauzy, et al.
Pageof 5